Long-term effects of involuntary hospitalization on medication adherence, treatment engagement and perception of coercion
- 1.5k Downloads
The purpose of the study was to examine the long-term influence of involuntary hospitalization on medication adherence, engagement in out-patient treatment and perceived coercion to treatment participation.
In a naturalistic observational multi-centre study, 290 voluntarily and 84 involuntarily hospitalized patients with schizophrenia or schizoaffective disorder had been followed up over a period of 2 years with half-yearly assessments. Assessments included self-rated medication adherence, externally judged medication adherence by blood levels, engagement in treatment and perceived coercion. The statistical analyses were based on multilevel hierarchical modelling of longitudinal data. Level and development of the outcome was controlled for involuntariness, for sociodemographic characteristics and clinical history.
Involuntariness of the index-hospitalization did not have an effect on the development of treatment engagement or medication adherence judged by blood levels in the course of the follow-up period when the models were controlled for sociodemographic variables and clinical history. It was associated, though, with a continuously lower self-rated medication adherence. Moreover, former involuntarily hospitalized patients more often felt coerced in several treatment aspects at the follow-up assessments. Yet, there was no difference between the voluntary and involuntary group with regard to the development of the levels of adherence or coercion experiences over time.
Involuntary hospitalization does not seem to impair future treatment engagement in patients with schizophrenia, but formerly involuntarily hospitalized patients continue to be more sensitive to subjective or real coercion in their treatment and more vulnerable to medication non-adherence. Hereby, their risk of future involuntary hospitalization might be increased.
KeywordsInvoluntary hospitalization Adherence Treatment engagement Schizophrenia
The ELAN study was funded as an investigator-initiated research project by a grant from AstraZeneca Deutschland to the University of Tübingen (Project Nr. 229/2004V—Version 2, 27.09.04). AstraZeneca had no role in the development of the research questions, the design of the study, the collection, analyses and interpretation of data, and the writing of the manuscript. AstraZeneca had the right to comment on the final draft of the article before the submission to the journal. We wish to thank all participants who participated in the study. We also thank Heike Wiesner, Filiz Özfirat, Tanja Gieselmann and Simone Triem for data collection and data entry and Ildiko Baumgartner for her work in processing data.
Conflict of interest
The authors declare that they have no conflict of interest.
- 18.Opjordsmoen S, Friis S, Melle I, Haahr U, Johannessen JO, Larsen TK, Røssberg JI, Rund BR, Simonsen E, Vaglum P, McGlashan TH (2010) A 2-year follow-up of involuntary admission’s influence upon adherence and outcome in first-episode psychosis. Acta Psychiatr Scand 121:371–376PubMedCrossRefGoogle Scholar
- 19.Kilian R, Steinert T, Schepp W, Weiser P, Jaeger S, Pfiffner C, Frasch K, Eschweiler GW, Messer T, Croissant D, Becker T, Längle G (2012) Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial. Eur Arch Psychiatry Clin Neurosci 262:589–598PubMedCrossRefGoogle Scholar
- 21.Frasch K, Weiser P, Becker T, Längle G, Steinert T, Niederreiner C, Pfiffner C, Jäger S, Bayer W, Eschweiler GW, Kilian R (2012) Psychotropic drug treatment, clinical characteristics and cognitive processing speed in patients with schizophrenia: results from the ELAN study. Pharmacopsychiatry 45:138–145PubMedCrossRefGoogle Scholar
- 22.Jaeger S, Pfiffner C, Weiser P, Kilian R, Becker T, Längle G, Eschweiler GW, Croissant D, Schepp W, Steinert T (2012) Adherence styles of schizophrenia patients identified by a latent class analysis of the Medication Adherence Rating Scale (MARS): a six-month follow-up study. Psychiatry Res 200:83–88PubMedCrossRefGoogle Scholar
- 23.Kay SR, Opler LA, Lindemeyer JP (1998) The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry 155:59–65Google Scholar
- 24.American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. DSM-IV-TR. 4th Edition, Text revision. American Psychiatric Association, Washington, DCGoogle Scholar
- 25.Jaeger S, Gebhardt RP, Pfiffner C, Bayer W, Weiser P, Wiesner H, Steinert T (2009) Akzeptanz und Umsetzung von Empfehlungen zur Rückfallverhütung–Entwicklung der Compliance Selbst-Rating Instrumente CSRI-E und CSRI-K. In: Schneider F, Grözinger M (eds) Psychische Erkrankungen in der Lebensspanne–Abstractband zum DGPPN Kongress 2009 in Berlin. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, BerlinGoogle Scholar
- 27.Muthén B, Asparouhov T (2011) Beyond multilevel regression modeling: Multilevel analysis in a general latent variable framework. In: Hox JJ, Roberts JK (eds) Handbook of advanced multilevel analysis. Taylor and Francis, New York, pp 15–40Google Scholar
- 28.Muthén LK, Muthen BO (1998–2010) Mplus user’s guide. Sixth edition. Muthén & Muthén, Los Angeles, CAGoogle Scholar
- 29.Pieters V (2003) Macht—Zwang—Sinn Subjektives Erleben, Behandlungsbewertungen und Therapieerfolge bei gerichtlichen Unterbringungen schizophrener Patienten. Psychiatrie-Verlag, BonnGoogle Scholar
- 40.Day JC (2003) How reflections on concordance in mental health can affect research and clinical practice in adherence. Pharm J 271:505–507Google Scholar
- 41.Fleischhacker WW, Oehl MA, Hummer M (2003) Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 64(Suppl):S10–S13Google Scholar